[GBIM] GlobeImmune, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.43 Change: 0.03 (7.5%)
Ext. hours: Change: 0 (0%)

chart GBIM

Refresh chart

Strongest Trends Summary For GBIM

GBIM is in the medium-term down -67% below S&P in 1 year. In the long-term down -80% below S&P in 2 years and down -99% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: GlobeImmune Inc. operates as a biopharmaceutical company. The company develops and manufactures Tarmogens, a molecular immunotherapy vaccine for the treatment of cancer and infectious diseases. Its products include GI-4000 for pancreas, non-small cell lung, colorectal, endometrial, and ovarian cancers, as well as melanoma and multiple myeloma; GI-6207 for the treatment of human epithelial cancers, including non-small cell lung cancer, colorectal, pancreas, breast, gastric, and medullary thyroid cancers; GI-6301, a Tarmogen used for the treatment of lung, breast, colon, bladder, kidney, ovary, uterus, and prostate cancers; and GS-4774 a therapeutic vaccine for chronic HBV infection. GlobeImmune, Inc. was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune Inc. in 2001. The company was founded in 1995 and is based in Louisville, Colorado.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -31.37% Sales Growth - Q/Q-21.38% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-99.57% ROE-375.42% ROI
Current Ratio3.27 Quick Ratio Long Term Debt/Equity Debt Ratio1.12
Gross Margin10.97% Operating Margin-107.64% Net Profit Margin-268.08% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-20 K Cash From Operating Activities-2.43 M Gross Profit1.03 M
Net Profit-1.56 M Operating Profit-1.56 M Total Assets15.44 M Total Current Assets14.94 M
Total Current Liabilities4.57 M Total Debt Total Liabilities11.35 M Total Revenue1.19 M
Technical Data
High 52 week0.6 Low 52 week0.1 Last close0.15 Last change49%
RSI54.51 Average true range0.03 Beta0.35 Volume14.17 K
Simple moving average 20 days6% Simple moving average 50 days1.64% Simple moving average 200 days-36.82%
Performance Data
Performance Week33.04% Performance Month-6.88% Performance Quart-5.16% Performance Half-40.4%
Performance Year-60.79% Performance Year-to-date-17.41% Volatility daily16.38% Volatility weekly36.62%
Volatility monthly75.05% Volatility yearly259.97% Relative Volume102.19% Average Volume7.74 K
New High New Low

News

2016-11-21 12:50:22 | What’s Next At GlobeImmune Inc GBIM?

2016-11-18 12:40:00 | Gilead CEO Resigns, Dumps GlobeImmune Pact GILD

2016-11-18 03:55:00 | 3:55 am Globelmmune provides corporate update; CEO resigns, Gilead terminates collaboration and license agreement

2016-11-17 18:10:13 | GlobeImmune Announces Updates

2016-07-28 13:04:30 | GLOBEIMMUNE INC Financials

2016-07-06 10:49:20 | Why Tesla, Apple, Alibaba, and Two Other Stocks Are Trending Today

2016-07-05 17:51:01 | GlobeImmune Announces Delisting and Deregistration of Common Stock

2016-07-05 16:44:41 | GLOBEIMMUNE INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T

2016-07-05 16:30:00 | GlobeImmune Announces Delisting and Deregistration of Common Stock

2016-06-16 13:42:06 | Why Korn/Ferry, AMD, Wells Fargo & Two Other Stocks Are in Spotlight Today

2016-05-19 16:32:40 | GLOBEIMMUNE INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T

2016-05-19 11:39:00 | 5 Stocks Under $10 Set to Soar

2016-05-12 09:08:54 | GLOBEIMMUNE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2016-05-12 07:27:02 | GlobeImmune Announces Updates and Financial Results for First Quarter 2016

2016-05-12 06:30:00 | GlobeImmune Announces Updates and Financial Results for First Quarter 2016

2016-05-12 06:21:29 | GLOBEIMMUNE INC Files SEC form 10-Q, Quarterly Report

2016-04-29 13:51:00 | Gilead Stock: Analyzing 5 Key Suppliers GILD

2016-03-21 13:49:57 | GlobeImmune, Inc. :GBIM-US: Earnings Analysis: Q4, 2015 By the Numbers

2016-03-21 11:13:42 | GlobeImmune, Inc. :GBIM-US: Earnings Analysis: 2015 By the Numbers

2016-03-16 09:24:32 | GLOBEIMMUNE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2016-03-16 06:30:00 | GlobeImmune Announces Updates and Financial Results for Full Year 2015

2016-03-16 06:08:06 | GLOBEIMMUNE INC Files SEC form 10-K, Annual Report

2016-03-11 12:03:00 | Best Stocks to Buy for March 2016, If You So Choose

2016-03-11 11:47:00 | Markets Rally Belatedly To ECB Bazooka GBIM

2016-02-23 16:12:18 | GLOBEIMMUNE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits

2015-11-13 09:12:21 | GLOBEIMMUNE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2015-11-13 06:30:00 | GlobeImmune Announces Third Quarter 2015 Results and Corporate Highlights

2015-11-13 06:15:29 | GLOBEIMMUNE INC Files SEC form 10-Q, Quarterly Report

2015-11-03 12:08:22 | GlobeImmune, Inc. – Value Analysis NASDAQ:GBIM : November 3, 2015

2015-09-30 11:04:29 | GlobeImmune, Inc. Earnings Q2, 2015

2015-09-03 22:16:00 | 4 Stocks Under $10 Triggering Breakout Trades

2015-08-14 06:30:00 | GlobeImmune Announces Second Quarter 2015 Results and Corporate Highlights

2015-08-13 06:30:00 | GlobeImmune Engages Cantor Fitzgerald as Financial Advisor to Assist With Evaluation of Strategic Options

2015-07-01 08:02:00 | Can Hepatitis B Be A Blockbuster Bug?

2015-05-27 06:50:36 | GlobeImmune, Gilead Hep B drug fails in mid-stage study